Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acetylcholine release at peripheral cholinergic nerve terminals refers to the process in which acetylcholine, a major neurotransmitter in both the central and peripheral nervous systems, is exocytosed from nerve endings into the synaptic cleft, particularly at sites such as neuromuscular junctions and autonomic ganglia. Release is triggered by presynaptic depolarization and calcium influx, facilitating vesicle fusion with the presynaptic membrane via the SNARE complex and VAChT, allowing acetylcholine to act rapidly on postsynaptic nicotinic or muscarinic receptors. Disruption of this process leads to profound neuromuscular or autonomic dysfunction, and it is a point of action for certain neurotoxins (e.g., botulinum toxin) and clinical disorders (e.g., myasthenia gravis).
Inhibition of vesicle fusion (e.g., botulinum toxin inhibits SNARE proteins), stimulation of vesicle release (e.g., black widow spider venom causes excessive release), and modulation of presynaptic calcium influx (e.g., Mg2+, specific disease states).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetylcholine release at peripheral cholinergic nerve terminals.